Scott Bassett, MD
Interventional Cardiology · The Woodlands, TXNPI 1073847042
Payments from drug & device makers
Across 335 payments — averaging $113.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$24K
- Boston Scientific$4K
- Medtronic$3K
- Abbott$3K
- Biotronik Inc.$909
- Abiomed$511
- plus $4K from 33 others
What the payments were for
- Consulting fees$20,00053%
- Travel & lodging$5,19614%
- Food & beverage$12,62033%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 43 | $23,893 |
| Boston Scientific | 50 | $3,559 |
| Medtronic(2 entities) | 35 | $2,611 |
| Abbott | 50 | $2,508 |
| Biotronik Inc. | 16 | $909 |
| Abiomed | 8 | $511 |
| Inari Medical, Inc. | 7 | $460 |
| Edwards Lifesciences | 13 | $413 |
| Cvrx, Inc. | 5 | $411 |
| W. L. Gore & Associates, Inc. | 4 | $277 |
| Pfizer | 12 | $259 |
| E.r. Squibb & Sons, L.L.C. | 13 | $224 |
| Boehringer Ingelheim | 5 | $198 |
| Amgen | 13 | $186 |
| Terumo Medical Corporation | 1 | $151 |
| Impulse Dynamics (USA) Inc. | 4 | $150 |
| Novartis | 7 | $137 |
| Merck | 7 | $133 |
| Imperative Care, Inc | 3 | $110 |
| AstraZeneca | 6 | $108 |
| Cardiofocus, Inc. | 1 | $98 |
| Johnson & Johnson | 6 | $97 |
| Biosense Webster, Inc. | 3 | $82 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Tactile Systems Technology Inc | 4 | $63 |
| Kestra Medical Technology Services, Inc. | 1 | $38 |
| Cardiva Medical, Inc. | 1 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Baxter Healthcare | 1 | $30 |
| Shockwave Medical, Inc | 1 | $24 |
| Angiodynamics, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Stryker | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| GE HealthCare | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ATRICLIP LAA EXCLUSION SYSTEM$22,357
- SYNERGY ABLATION SYSTEM$21,908
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$21,356
- ISOLATOR SURGICAL ABLATION SYSTEM$21,203
- DISSECTOR$21,203
- VersaCross Access Solution$1,995
- CARDIOMEMS$569
- BioMonitor$356
- Barostim Neo System$344
- FLOWTRIEVER CATHETER, S$328
- CT THROMBECTOMY SYSTEM KIT$328
- MitraClip System$298
- Ensite Cardiac Mapping System$274
- Acticor 7 VR-T DX$238
- Rivacor 7 DR-T$238
- Assurity Pacemaker$183
- GORE CARDIOFORM Septal Occluder$161
- Euphora$154
- ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY$151
- Impella$144
How this compares
$37,914 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 345 | $391,908 |
| XareltoRivaroxaban | 147 | $150,634 |
| EntrestoSacubitril/Valsartan | 125 | $144,875 |
| JardianceEmpagliflozin | 103 | $112,153 |
| MultaqDronedarone Hcl | 32 | $51,115 |
| BrilintaTicagrelor | 57 | $38,234 |
| Praluent PenAlirocumab | 34 | $24,510 |
| Repatha SureclickEvolocumab | 24 | $19,344 |
| FarxigaDapagliflozin Propanediol | 15 | $15,995 |
| NexletolBempedoic Acid | 20 | $9,990 |
| VascepaIcosapent Ethyl | 14 | $8,301 |
| Midodrine Hcl | 30 | $6,210 |
| Nebivolol Hcl | 64 | $5,196 |
| Metoprolol Succinate | 316 | $4,933 |
| Flecainide Acetate | 103 | $4,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $259 | $391,908345 claims |
| Johnson & JohnsonXarelto | $97 | $150,634147 claims |
| NovartisEntresto | $137 | $144,875125 claims |
| Boehringer IngelheimJardiance | $198 | $112,153103 claims |
| AstraZenecaBrilinta, Farxiga | $108 | $54,22872 claims |
| Sanofi-aventis U.S. LLCMultaq | $33 | $51,11532 claims |
| Esperion Therapeutics, Inc.Nexletol | $65 | $9,99020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in The Woodlands
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.